Premium
Expression of AID in malignant melanoma with BRAF V600E mutation
Author(s) -
Okura Risa,
Yoshioka Haruna,
Yoshioka Manabu,
Hiromasa Kana,
Nishio Daisuke,
Nakamura Motonobu
Publication year - 2014
Publication title -
experimental dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.108
H-Index - 96
eISSN - 1600-0625
pISSN - 0906-6705
DOI - 10.1111/exd.12402
Subject(s) - cytidine deaminase , melanoma , mutation , cancer research , somatic cell , activation induced (cytidine) deaminase , v600e , germline mutation , immunohistochemistry , somatic hypermutation , lymph node , point mutation , medicine , biology , pathology , gene , immunology , genetics , antibody , b cell
BRAF ‐activating somatic mutations often exist in malignant melanoma. The underlying molecular mechanism of somatic BRAF mutation inductions remained to be clear. Activation‐induced cytidine deaminase ( AID ), a member of a cytidine deaminase family, and APOBEC 3 B induce somatic mutations and recently have been indicated to be involved in the pathomechanism of several kinds of cancers. The aim of this study was to explore the expression level of AID and APOBEC 3 B in BRAF ‐mutation‐ containing malignant melanoma. Immunohistochemical study demonstrated that 9 of 10 malignant melanomas with high AID expression had BRAF V600E mutation. Eight of them developed multiorgan metastases or multiple lymph node metastases afterwards. Although the size of the patient panel was small, the results indicate that there might be an association between AID expression and BRAF mutation in melanoma.